Drug
Samuraciclib clinical trials
Also written CT7001.
- studies test it
- 6
- open now
- 3
- in phase 3
- 0
- first study started
- 2021
Keep track of what changes. Save the samuraciclib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
6 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 2
Carrick Therapeutics Limited (2) · Pfizer (1) · University Health Network, Toronto (1) · Hoffmann-La Roche (1) · University of Washington (1)
Often tested with
Tested in the same studies.
Vepdegestrant (1) · Gemcitabine (1) · Albumin-Bound Paclitaxel (1) · Paclitaxel (1) · Abemaciclib (1) · Ipatasertib (1) · Inavolisib (1) · Ribociclib (1)
Studies
Open first, then newest update. How each study uses samuraciclib is read from its arms, and is right about nine times in ten.
Testing it · 6
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT04802759Written as Samuraciclib
- Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic CancerRecruitingPhase 1University of WashingtonNCT07645651Written as Samuraciclib
- Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic CancerNot yet recruitingPhase 1/2University Health Network, TorontoNCT07665684Written as Samuraciclib + Gemcitabine & Nab-Paclitaxel
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)CompletedPhase 1/2PfizerNCT06125522Written as Samuraciclib
- A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast CancerCompletedPhase 1/2Carrick Therapeutics LimitedNCT05963997Written as Samuraciclib
- A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult ParticipantsCompletedPhase 2Carrick Therapeutics LimitedNCT05963984Written as Samuraciclib
Given in every arm · 1 — samuraciclib is usual care beside what is tested
Codes
What other systems call samuraciclib · ClinicalTrials.gg INT014809
- UNII (FDA) 46D4HS9ODASAMURACICLIBOne source FDA
- NCI Thesaurus C155652SamuraciclibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 46D4HS9ODA | SAMURACICLIB | One source FDA |
| NCI Thesaurus | C155652 | Samuraciclib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.